HROW Nasdaq

Harrow Health, Inc.

HROW P 29400 | $10.43 -3.87% -4.03% 680K

(0.0% 1d) (12.4% 1m) (-50.3% 1y) (0.0% 2d) (0.0% 3d) (-4.3% 7d) (17.71% volume)
Earnings Calendar: 2024-03-19
Market Cap: $ 368,832,356
http://www.harrowinc.com
Sec Filling | Patents | 133 employees

Harrow Health, Inc. engages in the development, production, and sale of innovative medications. It operates through the Pharmaceutical Compounding and Pharmaceutical Drug Development segments. The Pharmaceutical Compounding segment focuses on the operations of ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.

add to watch list Paper trade email alert is off

Press-releases

Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing
Published: 2024-04-02 (Crawled : 15:30) - biospace.com/
HROW P 29400 | $10.43 -3.87% -4.03% 680K

Health Technology

| -7.66% | O: -2.11% H: 0.96% C: -1.2%
million series pharmaceuticals

Harrow Announces Availability of VEVYE® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease
Published: 2024-01-11 (Crawled : 15:00) - biospace.com/
HROW P 29400 | $10.43 -3.87% -4.03% 680K

Health Technology

| 19.88% | O: 1.22% H: 0.2% C: -0.4%
vevye first disease eye

Harrow Completes Transfer of the TRIESENCE® New Drug Application
Published: 2023-11-29 (Crawled : 21:00) - biospace.com/
HROW P 29400 | $10.43 -3.87% -4.03% 680K

Health Technology

| 31.33% | O: 1.33% H: 3.95% C: -1.43%
triesence drug transfer application

Harrow to Present at Two Investor Conferences in November
Published: 2023-11-20 (Crawled : 13:30) - biospace.com/
HROW P 29400 | $10.43 -3.87% -4.03% 680K

Health Technology

| 31.92% | O: 0.78% H: 5.65% C: 4.76%

Harrow Will Release Third Quarter 2023 Financial Results on November 13, 2023
Published: 2023-10-30 (Crawled : 13:00) - biospace.com/
HROW P 29400 | $10.43 -3.87% -4.03% 680K

Health Technology

| -13.79% | O: 1.75% H: 1.08% C: 0.65%
financial results

Melt Pharmaceuticals Announces Exclusive Development and License Agreement with Catalent for Its Zydis® Fast-Dissolve Technology for Use in MELT-300 for Needle- and Opioid-Free Procedural Sedation
Published: 2023-09-26 (Crawled : 13:00) - biospace.com/
HROW P 29400 | $10.43 -3.87% -4.03% 680K

Health Technology

| -20.14% | O: -0.07% H: 0.47% C: -5.14%
melt-300 zydis license pharmaceuticals technology agreement

Harrow to Announce Second Quarter 2023 Financial Results on August 9, 2023
Published: 2023-07-26 (Crawled : 16:00) - biospace.com/
HROW P 29400 | $10.43 -3.87% -4.03% 680K

Health Technology

| -44.32% | O: 0.0% H: 1.27% C: 0.28%
financial results

Harrow Prices $60 Million Public Offering of Common Stock
Published: 2023-07-19 (Crawled : 12:20) - biospace.com/
HROW P 29400 | $10.43 -3.87% -4.03% 680K

Health Technology

| -35.3% | O: 2.41% H: 20.84% C: 15.07%
offering

Harrow to Participate in B. Riley Securities 23rd Annual Institutional Investor Conference on May 24, 2023
Published: 2023-05-17 (Crawled : 14:00) - biospace.com/
HROW P 29400 | $10.43 -3.87% -4.03% 680K

Health Technology

| -43.82% | O: 0.33% H: 2.56% C: 2.37%
conference

Harrow to Launch FDA-Approved IHEEZO™ at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
Published: 2023-05-04 (Crawled : 14:00) - biospace.com/
HROW P 29400 | $10.43 -3.87% -4.03% 680K

Health Technology

| -53.63% | O: 0.47% H: 4.37% C: 0.47%
meeting

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0001493152-24-015410	4	2024-04-19	2024-04-19	Buy	P	29400	3775000
0001493152-24-011815	4	2024-03-28	2024-03-28	Buy	P	50000	3745600
0001493152-24-011071	4	2024-03-25	2024-03-22	Buy	P	9000	2137525
0001493152-24-010936	4	2024-03-22	2024-03-20	Buy	P	50600	3695600